» Articles » PMID: 30559077

Preparation of Low Molecular Weight Heparin Using an Ultrasound-assisted Fenton-system

Overview
Specialty Radiology
Date 2018 Dec 19
PMID 30559077
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Heparin, a high-molecular weight acidic polysaccharide, has raised much interest in the field of biomedical research due to its multiple bio-functions. The anticoagulant application of heparin in routine clinical practice, however, has been limited as the large molecular size of heparin can reduce its subcutaneous bioavailability and lead to severe adverse consequences such as thrombocytopenia. Here, we report a highly efficient and convenient method to depolymerize high-molecular weight, unfractionated heparin (UFH), into low molecular weight heparin (LMWH) by combining physical ultrasonic treatment with the chemical Fenton reaction, referred to as sono-Fenton. We found that this combination treatment synergistically degraded UFH into a LMWH of 4.87 kDa within 20 min. We characterized the mechanism of sono-Fenton heparin degradation through multiple approaches, including HPLC-SAX, disaccharide composition, FT-IR, NMR and top-down analysis, and found that the uronic acid residue in heparin was the most susceptible site attacked by OH radicals produced in the sono-Fenton process. Importantly, the LMWH prepared by this method had significantly higher anticoagulant activity than UFH and other LMWHs. This approach represents an effective method to produce heparin with improved activity and should be potentially useful for heparin production in the pharmaceutical industry.

Citing Articles

Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy.

Sultana R, Kamihira M Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459002 PMC: 11510354. DOI: 10.3390/ph17101362.


Legumes as an alternative protein source in plant-based foods: Applications, challenges, and strategies.

Zhang X, Zhang Z, Shen A, Zhang T, Jiang L, El-Seedi H Curr Res Food Sci. 2024; 9:100876.

PMID: 39435454 PMC: 11491897. DOI: 10.1016/j.crfs.2024.100876.


Non-Anticoagulant Activities of Low Molecular Weight Heparins-A Review.

Feng K, Wang K, Zhou Y, Xue H, Wang F, Jin H Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765064 PMC: 10537022. DOI: 10.3390/ph16091254.


Mechanism analysis of hydroxypropyl guar gum degradation in fracture flowback fluid by homogeneous sono-Fenton process.

Wang F, Sun Z, Shi X, Wang L, Zhang W, Zhang Z Ultrason Sonochem. 2023; 93:106298.

PMID: 36641871 PMC: 9860363. DOI: 10.1016/j.ultsonch.2023.106298.


Advances in the preparation and synthesis of heparin and related products.

Baytas S, Linhardt R Drug Discov Today. 2020; 25(12):2095-2109.

PMID: 32947045 PMC: 7718634. DOI: 10.1016/j.drudis.2020.09.011.


References
1.
Sasisekharan R, Venkataraman G . Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol. 2000; 4(6):626-31. DOI: 10.1016/s1367-5931(00)00145-9. View

2.
Hirsh J, Raschke R . Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl):188S-203S. DOI: 10.1378/chest.126.3_suppl.188S. View

3.
Wardrop D, Keeling D . The story of the discovery of heparin and warfarin. Br J Haematol. 2008; 141(6):757-63. DOI: 10.1111/j.1365-2141.2008.07119.x. View

4.
Buyue Y, Sheehan J . Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite. Blood. 2009; 114(14):3092-100. PMC: 2756211. DOI: 10.1182/blood-2009-02-203661. View

5.
Vismara E, Pierini M, Mascellani G, Liverani L, Lima M, Guerrini M . Low-molecular-weight heparin from Cu2+ and Fe2+ Fenton type depolymerisation processes. Thromb Haemost. 2010; 103(3):613-22. DOI: 10.1160/TH09-02-0084. View